Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumicitabine PK Interaction with Piperacillin/Tazobactam
NCT03441529Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lumicitabine in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of JNJ-63549109, Area Under Plasma Concentration Time Curve From Time Zero to Last Quantifiable of JNJ-63549109 and 6 more. Started Feb 2018; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03441529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03441529.